192 related articles for article (PubMed ID: 28707435)
1. Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Kim JJ
Cancer Med; 2017 Aug; 6(8):2008-2014. PubMed ID: 28707435
[TBL] [Abstract][Full Text] [Related]
2. Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Kim JJ
BMC Cancer; 2017 Nov; 17(1):791. PubMed ID: 29178896
[TBL] [Abstract][Full Text] [Related]
3. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
[TBL] [Abstract][Full Text] [Related]
4. Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.
Campos NG; Sharma M; Clark A; Kim JJ; Resch SC
PLoS One; 2016; 11(10):e0164000. PubMed ID: 27711124
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
Campos NG; Castle PE; Wright TC; Kim JJ
Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
[TBL] [Abstract][Full Text] [Related]
6. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
8. Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.
Pimple SA; Mishra GA
Minerva Ginecol; 2019 Oct; 71(5):365-371. PubMed ID: 31698891
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening in a low-resource setting: a pilot study on an HPV-based screen-and-treat approach.
Kunckler M; Schumacher F; Kenfack B; Catarino R; Viviano M; Tincho E; Tebeu PM; Temogne L; Vassilakos P; Petignat P
Cancer Med; 2017 Jul; 6(7):1752-1761. PubMed ID: 28580596
[TBL] [Abstract][Full Text] [Related]
10. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus testing in the prevention of cervical cancer.
Schiffman M; Wentzensen N; Wacholder S; Kinney W; Gage JC; Castle PE
J Natl Cancer Inst; 2011 Mar; 103(5):368-83. PubMed ID: 21282563
[TBL] [Abstract][Full Text] [Related]
12. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Cervical Cancer in Low-Resource African Settings.
Mulongo M; Chibwesha CJ
Obstet Gynecol Clin North Am; 2022 Dec; 49(4):771-781. PubMed ID: 36328679
[TBL] [Abstract][Full Text] [Related]
14. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
16. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.
Campos NG; Maza M; Alfaro K; Gage JC; Castle PE; Felix JC; Cremer ML; Kim JJ
Int J Cancer; 2015 Aug; 137(4):893-902. PubMed ID: 25639903
[TBL] [Abstract][Full Text] [Related]
17. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
18. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
[TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
20. Opportunities and challenges for introducing HPV testing for cervical cancer screening in sub-Saharan Africa.
Tsu VD; Njama-Meya D; Lim J; Murray M; de Sanjose S
Prev Med; 2018 Sep; 114():205-208. PubMed ID: 30031013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
